All posts in News

Trulicity FDA approval : Eli Lilly and Company (Lilly) has secured approval from the US Food and Drug Administration (FDA) for Trulicity (dulaglutide) to reduce major cardiovascular events (MACE) in type 2 diabetes patients having established cardiovascular (CV) disease or multiple cardiovascular risk factors.

The latest FDA approval Trulicity means that the drug the first and only type 2 diabetes medicine indicated for reducing the risk of MACE for primary as well as secondary prevention populations. The Lilly diabetes drug is a weekly injectable glucagon-like peptide 1 receptor agonist (GLP-1 RA). Read more

March 17, 2020

South San Francisco, CA, March 17, 2020, — Circle Pharma, Inc., a macrocycle drug discovery and development company focused on intractable cancer targets, today announced that it has raised $45 million in a Series B financing.

The financing was led by The Column Group, with participation by Nextech Invest.  All investors from the prior round – ShangPharma, LifeForce Capital, and the Berkeley Catalyst Fund – joined the financing. Read more

NESS-ZIONA, Israel I February 13, 2020 I VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, is pleased to announce that it has completed in silico analyses and believes that it has successfully identified a corona virus (COVID-19) vaccine candidate (“Vaccine Candidate”). Read more

PISCATAWAY, N.J., Jan. 15, 2020 /PRNewswire/ --GenScript, a world leading biotechnology company, announced its support today of Avidea Technologies' efforts to develop a groundbreaking peptide-based personalized cancer vaccine. Read more

MENLO PARK, Calif., March 12, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat chronic diseases and extend healthy lifespan, today reported its financial results for the fourth quarter ended December 31, 2019. Read more.

Repertoire Immune Medicines officially launched this morning following the merger of two complementary Flagship Pioneering companies, Torque Therapeutics and Cogen Immune Medicines. The new company is focused on tapping into the powers of the immune system to address numerous diseases. Read more.

• Immunotherapy using LEAPS peptide technology may be able to reduce COVID-19 viral load and tissue damage resulting from infection in the lungs.
• Studies conducted in collaboration with NIAID showed LEAPS peptides reduced morbidity and mortality in mice with another respiratory virus, pandemic influenza (H1N1).

VIENNA, VA, USA I March 9, 2020 I CEL-SCI Corporation (NYSE American: CVM) announces that it is developing an immunotherapy with the potential to treat the COVID-19 coronavirus using its patented LEAPS peptide technology. The LEAPS peptides will utilize conserved regions of coronavirus proteins to stimulate protective cell mediated T cell responses and reduce viral load. The LEAPS peptide technology can be used to construct immunotherapeutic peptides that exhibit both antiviral and anti-inflammatory properties. Consequently, these products not only target the virus infection against which they are directed, but also elicit the appropriate protective response(s) against it. Read more.

Genentech is teaming up with Bicycle Therapeutics to develop cancer immunotherapies. Bicycle uses chemical scaffolds to turn linear peptides into two pretzel-like loops. The firm says these so-called bicyclic peptides can be used as drugs alone or to deliver toxic payloads to cancer cells. Bicycle has several cancer drug programs of its own. Genentech will pay Bicycle $30 million up front—and up to $1.7 billion in milestone payments—to develop bicyclic peptides against several new targets. Read more

Novel Mechanism of Action Inhibits Pathological Activation of Microglial Cells and Prevents Neuronal Cell Death

GERMANTOWN, MD, USA I March 03, 2020 Neuraly, a clinical stage biotechnology company pioneering disease-modifying agents for neurodegenerative disorders, today announced the dosing of the first patient in its Phase 2 clinical trial of NLY01 for Parkinson’s disease. Read more.

The 36-month project is a collaboration with MD Anderson Cancer Center in Houston and will advance a novel therapeutic for triple-negative breast cancer to the point of pre-IND meeting with the FDA

EnduRx Pharmaceuticals, advancing a drug delivery system intended to improve outcomes for patients with hard-to-treat solid tumors, has been awarded $1.4 million dollar Department of Defense grant. The 36-month project is a collaboration with MD Anderson Cancer Center in Houston and will advance a novel therapeutic for triple-negative breast cancer to the point of pre-IND meeting with the FDA. Total project grant award is $1.75 million dollars. Read more.